Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415667 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL1404103 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL1404087 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL3201636 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL1619625 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL1619327 | 0.98 | MAOB (0.50) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL1404079 | 0.94 | MAOB (0.46) | MAOBDAOSLC2A1KDM1ATP53 | |
| SCHEMBL6656793 | 0.89 | MAOB (0.56) | MAOBDAOSLC2A1KDM1AMAOA | |
| SCHEMBL6663625 | 0.87 | MAOB (0.57) | MAOBDAOSLC2A1KDM1AMAOA | |
| SCHEMBL436938 | 0.85 | ALDH1A1 (0.46) | MAOBDAOKDM1AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| US-10174349-B2 | Recombinant cell producing 2-hydroxyisobutyric acid | EVONIK ROEHM GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-2291530-B1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK ROEHM GMBH (DE) | 2018-12-26 | — | — | EP | disclosed |
| CN-107083352-A | Produce the recombinant cell of 2 hydroxy-iso-butyric acids | 赢创罗姆有限公司 | 2017-08-22 | — | — | CN | disclosed |
| EP-2125771-B1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK ROEHM GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207371-B2 | Process for preparing (meth)acrylic acid | EVONIK RÖHM GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110171702-A1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK ROEHM GMBH (DE) | 2011-07-14 | — | — | US | disclosed |
| US-7928251-B2 | Process for preparing tetramethyl glycolide | EVONIK ROEHM GMBH (DE) | 2011-04-19 | — | — | US | disclosed |
| EP-2291530-A1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | Evonik Röhm GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20100029979-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | EVONIK ROEHM GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100010276-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK ROEHM GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009156214-A1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK RÖHM GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
| EP-2125771-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | Evonik Röhm GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2091906-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | Evonik Röhm GmbH (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008061819-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | EVONIK RÖHM GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061821-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK RÖHM GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029979-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | MMAB, ASS1, PAM | MAOB 1541/4885DAO 109/4885SLC2A1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.